PTC Therapeutics (PTCT) Tops Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.03), $0.19 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $23 million versus the consensus estimate of $19.76 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 1stdibs.Com, Inc. (DIBS) Tops Q3 EPS by 2c ; Offers Guidance
- Zoetis (ZTS) Tops Q3 EPS by 24c; offers guidance
- Apyx Medical Corp. (APYX) Tops Q3 EPS by 6c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
